-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
Technology
Zealand Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based products that target indications (diseases and symptoms) of significant unmet clinical need and commercial potential.
Since 1999, Zealand’s scientists have built a pipeline that includes three compounds in clinical phase II development and two compounds in clinical phase I development. In addition, two compounds are in pre-clinical development.
As part of the Company’s operations, Zealand Pharma has formed clinical development partnerships with the leading pharmaceutical companies, Sanofi-Aventis and Wyeth.
Zealand Pharma’s specialized know-how in peptide chemistry enables the generation of novel peptide molecules with unique therapeutic qualities.
One of the aims of Zealand Pharma’s proprietary SIP®-technology is to optimize the therapeutic profile of a broad range of active peptides (e.g., increased efficacy, increased drug stability, and increased persistence in the human body).
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.